Abstract
Background: The objectivity of assessing histopathological tumor response to neoadjuvant therapy (NAT) in resected pancreatic cancer specimens remains debated. This project aims to investigate the interobserver agreement of current tumor response scoring (TRS) systems.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
